Dutch medical technology company Microsure has secured CE mark approval for its MUSA-3 system and appointed Alex Joseph as its new CEO, taking over from Iwan van Vijfeijken.
With the CE mark, the company can now deploy the MUSA-3 system for clinical use across Europe, moving from product development to a clinical medical device business, where it aims to gather evidence and support adoption among medical centres.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company will concentrate on generating clinical data at European sites, forming collaborations, and evaluating how the MUSA-3 system facilitates super-microsurgical procedures.
The system is intended to provide assistance during open super-microsurgical interventions by enabling surgeons to achieve finer and more stable hand movements.
Its intended uses include supporting procedures on small anatomical structures such as lymphatic ducts, blood vessels, and nerves, with applications in free flap operations, lymphatic procedures, and peripheral nerve repairs.
The leadership change aligns with this shift, as Joseph steps in as CEO after contributing significantly to MUSA-3’s development. He brings experience in surgical robotics and regulated medical devices.
Joseph said: “As I step into the role of CEO, Microsure is entering a new phase. With the CE mark now achieved, our focus is on generating clinical evidence and demonstrating the value of our technology in practice.”
Microsure has acknowledged Iwan van Vijfeijken for his leadership during its key developmental period in which it advanced the MUSA-3 system and achieved regulatory approval.
As the company moves forward, it will focus on clinical adoption, evidence generation, and laying the groundwork for potential broader commercialisation of the technology.
